These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

197 related articles for article (PubMed ID: 33786374)

  • 1. Potent SARS-CoV-2 Direct-Acting Antivirals Provide an Important Complement to COVID-19 Vaccines.
    Pelly S; Liotta D
    ACS Cent Sci; 2021 Mar; 7(3):396-399. PubMed ID: 33786374
    [No Abstract]   [Full Text] [Related]  

  • 2. Therapeutic developments for SARS-CoV-2 infection-Molecular mechanisms of action of antivirals and strategies for mitigating resistance in emerging variants in clinical practice.
    Săndulescu O; Apostolescu CG; Preoțescu LL; Streinu-Cercel A; Săndulescu M
    Front Microbiol; 2023; 14():1132501. PubMed ID: 36937282
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Inhibition of Human Coronaviruses by Combinations of Host-Targeted and Direct-Acting Antivirals.
    de León P; Cañas-Arranz R; Bustos MJ; Sáiz M; Sobrino F
    Antimicrob Agents Chemother; 2023 Apr; 67(4):e0170322. PubMed ID: 36975844
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Rescue of SARS-CoV-2 from a Single Bacterial Artificial Chromosome.
    Ye C; Chiem K; Park JG; Oladunni F; Platt RN; Anderson T; Almazan F; de la Torre JC; Martinez-Sobrido L
    mBio; 2020 Sep; 11(5):. PubMed ID: 32978313
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Design of Potent Membrane Fusion Inhibitors against SARS-CoV-2, an Emerging Coronavirus with High Fusogenic Activity.
    Zhu Y; Yu D; Yan H; Chong H; He Y
    J Virol; 2020 Jul; 94(14):. PubMed ID: 32376627
    [TBL] [Abstract][Full Text] [Related]  

  • 6. SARS-CoV-2 RNA shedding in recovered COVID-19 cases and the presence of antibodies against SARS-CoV-2 in recovered COVID-19 cases and close contacts, Thailand, April-June 2020.
    Chirathaworn C; Sripramote M; Chalongviriyalert P; Jirajariyavej S; Kiatpanabhikul P; Saiyarin J; Soudon C; Thienfaidee O; Palakawong Na Ayuthaya T; Brukesawan C; Chaiwanichsiri D; Intharasongkroh D; Wanlapakorn N; Chansaenroj J; Puenpa J; Yorsaeng R; Thitithanyanont A; Kitphati R; Mungaomklang A; Nagavajara P; Poovorawan Y
    PLoS One; 2020; 15(10):e0236905. PubMed ID: 33119712
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Consensus summary report for CEPI/BC March 12-13, 2020 meeting: Assessment of risk of disease enhancement with COVID-19 vaccines.
    Lambert PH; Ambrosino DM; Andersen SR; Baric RS; Black SB; Chen RT; Dekker CL; Didierlaurent AM; Graham BS; Martin SD; Molrine DC; Perlman S; Picard-Fraser PA; Pollard AJ; Qin C; Subbarao K; Cramer JP
    Vaccine; 2020 Jun; 38(31):4783-4791. PubMed ID: 32507409
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pharmacological approach for the reduction of inflammatory and prothrombotic hyperactive state in COVID-19 positive patients by acting on complement cascade.
    Vitiello A; La Porta R; D'Aiuto V; Ferrara F
    Hum Immunol; 2021 Apr; 82(4):264-269. PubMed ID: 33632561
    [TBL] [Abstract][Full Text] [Related]  

  • 9. COVID-19 and paediatric challenges: An interview with Professor of Paediatrics Vana Papaevangelou (University of Athens School of Medicine).
    Mammas IN; Theodoridou M; Spandidos DA
    Exp Ther Med; 2020 Dec; 20(6):296. PubMed ID: 33209140
    [TBL] [Abstract][Full Text] [Related]  

  • 10. DNA Oligonucleotides as Antivirals and Vaccine Constituents against SARS Coronaviruses: A Prospective Tool for Immune System Tuning.
    Oberemok VV; Andreeva OA; Alieva EE
    Int J Mol Sci; 2023 Jan; 24(2):. PubMed ID: 36675069
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical Trials of Repurposed Antivirals for SARS-CoV-2.
    Martinez MA
    Antimicrob Agents Chemother; 2020 Aug; 64(9):. PubMed ID: 32631826
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Novel and potent inhibitors targeting DHODH are broad-spectrum antivirals against RNA viruses including newly-emerged coronavirus SARS-CoV-2.
    Xiong R; Zhang L; Li S; Sun Y; Ding M; Wang Y; Zhao Y; Wu Y; Shang W; Jiang X; Shan J; Shen Z; Tong Y; Xu L; Chen Y; Liu Y; Zou G; Lavillete D; Zhao Z; Wang R; Zhu L; Xiao G; Lan K; Li H; Xu K
    Protein Cell; 2020 Oct; 11(10):723-739. PubMed ID: 32754890
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Rescue of SARS-CoV-2 from a single bacterial artificial chromosome.
    Ye C; Chiem K; Park JG; Oladunni F; Platt RN; Anderson T; Almazan F; de la Torre JC; Martinez-Sobrido L
    bioRxiv; 2020 Jul; ():. PubMed ID: 32743573
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Optimization Rules for SARS-CoV-2 M
    Stoddard SV; Stoddard SD; Oelkers BK; Fitts K; Whalum K; Whalum K; Hemphill AD; Manikonda J; Martinez LM; Riley EG; Roof CM; Sarwar N; Thomas DM; Ulmer E; Wallace FE; Pandey P; Roy S
    Viruses; 2020 Aug; 12(9):. PubMed ID: 32859008
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Lack of antiviral activity of darunavir against SARS-CoV-2.
    De Meyer S; Bojkova D; Cinatl J; Van Damme E; Buyck C; Van Loock M; Woodfall B; Ciesek S
    Int J Infect Dis; 2020 Aug; 97():7-10. PubMed ID: 32479865
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Re-purposing of hepatitis C virus FDA approved direct acting antivirals as potential SARS-CoV-2 protease inhibitors.
    Uddin R; Jalal K; Khan K; Ul-Haq Z
    J Mol Struct; 2022 Feb; 1250():131920. PubMed ID: 34815586
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Antiviral Drug Discovery for the Treatment of COVID-19 Infections.
    Ng TI; Correia I; Seagal J; DeGoey DA; Schrimpf MR; Hardee DJ; Noey EL; Kati WM
    Viruses; 2022 May; 14(5):. PubMed ID: 35632703
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Complement Factors in COVID-19 Therapeutics and Vaccines.
    Kurtovic L; Beeson JG
    Trends Immunol; 2021 Feb; 42(2):94-103. PubMed ID: 33402318
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Frequency and Duration of SARS-CoV-2 Shedding in Oral Fluid Samples Assessed by a Modified Commercial Rapid Molecular Assay.
    Bordi L; Sberna G; Lalle E; Piselli P; Colavita F; Nicastri E; Antinori A; Boumis E; Petrosillo N; Marchioni L; Minnucci G; D'Agostini E; Castilletti C; Locatelli F; Zumla A; Ippolito G; Capobianchi MR; On Behalf Of Inmi ReCOVeRI Study Group
    Viruses; 2020 Oct; 12(10):. PubMed ID: 33092065
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The Long Road Toward COVID-19 Herd Immunity: Vaccine Platform Technologies and Mass Immunization Strategies.
    Frederiksen LSF; Zhang Y; Foged C; Thakur A
    Front Immunol; 2020; 11():1817. PubMed ID: 32793245
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.